Silo Pharma announces board-authorized stock repurchase program up to $1M

Silo Pharma, Inc.

Board authorized repurchase of up to $1M of common stock in open market or privately negotiated transactions.
Company had approximately 3,138,797 shares outstanding as of November 10, 2022.
Repurchases subject to available liquidity, cash flows, market conditions, and regulatory limits.
Program does not obligate the company to repurchase any specific amount and may be suspended or discontinued any time.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.